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Background: The Polo-like Kinase 1 (PLK1) protein regulates cell cycle progression and is overexpressed in many
malignant tissues. Overexpression is associated with poor prognosis in several cancer entities, whereby expression
of PLK1 shows high inter-individual variability. Although PLK1 is extensively studied, not much is known about the
genetic variability of the PLK1 gene. The function of PLK1 and the expression of the corresponding gene could be
influenced by genomic variations. Hence, we investigated the gene for functional polymorphisms. Such polymorphisms
could be useful to investigate whether PLK1 alters the risk for and the course of cancer and they could have an impact
on the response to PLK1 inhibitors.
Methods: The coding region, the 5′ and 3′UTRs and the regulatory regions of PLK1 were systematically sequenced.
We determined the allele frequencies and genotype distributions of putatively functional SNPs in 120 Caucasians
and analyzed the linkage and haplotype structure using Haploview. The functional analysis included electrophoretic
mobility shift assay (EMSA) for detected variants of the silencer and promoter regions and reporter assays for a 3′UTR
polymorphism.
Results: Four putatively functional polymorphisms were detected and further analyzed, one in the silencer region
(rs57973275), one in the core promoter region (rs16972787), one in intron 3 (rs40076) and one polymorphism in the
3′untranslated region (3′UTR) of PLK1 (rs27770). Alleles of rs27770 display different secondary mRNA structures and
showed a distinct allele-dependent difference in mRNA stability with a significantly higher reporter activity of the
A allele (p < 0.01).
Conclusion: The present study provides evidence that at least one genomic variant of PLK1 has functional properties
and influences expression of PLK1. This suggests polymorphisms of the PLK1 gene as an interesting target for further
studies that might affect cancer risk, tumor progression as well as the response to PLK1 inhibitors.
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Polo-like kinases (PLKs) belong to the family of serin/
threonin kinases. They are involved in the regulation of
cell division and centrosome cycle. Until now, four hu-
man PLKs have been identified. PLK1 is so far the best
characterized polo-like kinase and a target for anticancer
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1Institute of Pharmacogenetics, University Hospital Essen, Hufelandstr. 55,
45147 Essen, Germany
Full list of author information is available at the end of the article
© 2014 Akdeli et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.PLK1 promotes proliferation by supporting mitotic
entry and inhibits apoptosis by interaction with p53 [3-5].
PLK1 is up-regulated in many different tumour tissues like
head and neck squamous cell carcinoma, oesophagus and
stomach cancer, ovarian cancer, non-small cell lung can-
cer, liver cancer, cervical cancer and breast cancer [6-9].
Overexpression of PLK1 has been suggested as a bio-
marker for numerical chromosomal aberration [10,11].
Furthermore, overexpression is associated with poor prog-
nosis in several cancer entities [9,12-15]. Consistent with
these findings, different PLK1 inhibitors, i.e. small mole-
cules as well as an siRNA-based formulation, are currentlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cancer drugs [16-18].
The human PLK1 locus maps on chromosome 16p12.1,
and the gene product comprises 10 exons and codes for a
67 kDa protein [19,20]. The 5′ region of PLK1 harbors
three distinct regulatory regions. Next to the translation
initiation site is the core promoter region of the gene. This
region mediates up to 75% of the promoter activity and is
followed by an extended promoter region with lower im-
pact on activity. A silencer region which is able to sup-
press about 50% of the activity and an enhancer region are
located distal to the promoter region (Figure 1A) [21].
Polymorphisms within the above mentioned gene regions
can exert functional impact upon gene expression and
protein function. In particular single nucleotide polymor-
phisms (SNPs) can be useful in association studies for
studying complex genetic disorders by a candidate gene
approach [22]. Functional polymorphisms are of interest
in cancer research and treatment, because they could be
used to analyze cancer risk and outcome as well as the re-
sponse to therapeutic agents [23]. Until now, two reports
indicate a possible impact of genetic variants on PLK1
function. In a genome wide bioinformatic approach a
polymorphism of the PLK1 3′UTR (rs27770) was one of
117 variants that were predicted to be functional due to
significant allele frequency deviations between HapMap












































Figure 1 The PLK1 gene locus and genetic variants. Structure of the PL
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to the other are shown for haplotypes with a frequency of at least 10% (thpart of a polymorphism panel, another polymorphism lo-
cated within intron 3 of PLK1 (rs40076) has been sug-
gested as an outcome predictor for Caucasian bladder
cancer patients [25].
PLK1 is an important oncogene and drug target in many
cancer entities. Genetic variability of such proteins can
have an impact upon the risk and the outcome of different
cancer types as well as the response of an individual to
drug treatments [27,28]. Until now, only very limited in-
formation about functionally relevant genetic variations of
the PLK1 gene is available. The aim of this study was to
systematically search for functional polymorphisms in the
PLK1 gene, which could alter gene expression or protein
function. We reviewed dbSNP and HapMap data and se-
quenced functionally relevant regions of PLK1. Retrieved
polymorphisms were analyzed by in silico methods to pre-
dict functional polymorphisms. Four SNPs were selected
for further evaluation and analyzed for linkage and haplo-
type structure. We identified rs27770 as a functional poly-
morphism that modulates the secondary structure and
stability of PLK1mRNA.
Results
Sequencing results of the PLK1 gene and linkage analysis
of SNPs in regulatory regions
Data base analysis and PLK1 sequencing in healthy unre-
lated Caucasians revealed 49 SNPs with a minor allele3‘
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like insertions/deletions or repeats. The PLK1 coding re-
gion harbors no polymorphisms, whereas most of the
SNPs where located in introns. Analysis of these intronic
SNPs revealed that none of them is located within puta-
tively functional regions (e.g. exon-intron boundaries or
branch points), therefore, it is unlikely that they have
functional properties, e.g. alteration of splicing. Three
SNPs which occur in Caucasians were detected in regu-
latory regions and further investigated (Figure 1A). They
are located in the silencer (rs57973275), in the promoter
(rs16972787), and in the 3′UTR (rs27770). Additionally,
we analyzed the genotype distribution and linkage of
rs40076 in intron 3 based on the suggested association
with survival of bladder cancer patients [25]. Table 1
shows the genotype distributions and allele frequen-
cies of these polymorphisms. All distributions were
compatible with Hardy-Weinberg equilibrium. The 5′-
region SNPs rs57973275 and rs16972787 showed the
same low MAF of 1.7%. They are in complete linkage to
each other. Further linkage analysis using haploview
(Figure 1B) revealed strong linkage disequilibrium be-
tween all four SNPs (D′ 0.95 to 1.0), whereas the correl-
ation was high only for the pairs rs57973275/rs16972787
(r2 1.0) and rs40076/rs27770 (r2 0.89), but weak for other
pairwise comparisons (r2 0.01 to 0.05). Analysis of the two
haplotype blocks showed a D′ of 0.78 between blocks
(Figure 1C). In line with these results, we identified 3
major haplotypes (GGAA, GGGG and AAGA) with a fre-
quency above 1% (Figure 1D). These haplotypes represent
98.8% of all detected allele combinations of our Caucasian
study population. Two rare haplotypes could be detected,
one with a frequency of 0.8% (GGAG) and another with a
frequency of 0.4% (AAGG).Table 1 Genotype distributions and allele frequencies in
healthy Caucasians
SNP Genotype n (%) Allele frequency HWE P
rs57973275 GG 116 (96.7) G 0.98
GA 4 (3.3) A 0.02 0.85
AA 0
rs16972787 GG 116 (96.7) G 0.98
GA 4 (3.3) A 0.02 0.85
AA 0
rs40076 AA 68 (56.7) A 0.77
AG 48 (40.0) G 0.23 0.20
GG 4 (3.3)
rs27770 AA 71 (59.2) A 0.77
AG 43 (35.8) G 0.23 0.88
GG 6 (5.0)rs57973275 (c.-1706 G > A) and rs16972787 (c.-233G > A)
alleles generate different putative transcription factor
binding sites
Functional polymorphisms in the silencer and promoter
region may impair mRNA levels by changing transcrip-
tion factor (TF) binding sites and concurrent modulation
of the promoter activity. We predicted potential allele-
dependent TF binding using MatInspector, Alibaba2 and
Consite (Figure 2A) [29-31]. For rs57973275 a putative
binding site of the TF Activator protein 1 (AP1) emerged
for the G allele and C-Rel for the A allele. In the pres-
ence of the A allele, rs16972787 created binding sites for
PAX-2 (Paired box gene 2), PAX-6 (Paired box gene 6)
and Snail, as well as a MEF3 binding motif, whereas the
same binding sites are not present for the G allele, which
instead carries a putative binding site for KLF7 (Krueppel
like transcription factor 7). We used these in silico results
to design oligonucleotides which comprise the putative
binding sites of the different TFs. To analyze differences
between the alleles we performed electrophoretic mobility
shift assays (EMSA) with these oligonucleotides. Nuclear
extracts of three different cell lines (HEK293, HepG2 and
HeLa) were used for both SNPs to cover the diversity of
the predicted TFs. All three cell lines are known to ex-
press (HEK293) and overexpress (HepG2 and HeLa)
PLK1 [32-34]. Figure 2B shows two representative results
of these experiments. In contrast to the in silico results we
were not able to detect any specific transcription factor
binding to the alleles of both polymorphisms.
rs27770 (c.*154A > G) alleles generate different secondary
mRNA structures and the A allele leads to increased
expression in HEK293 reporter assays
To study whether microRNA binding, mRNA folding or
regulatory RNA elements could be altered by rs27770,
we performed bioinformatic analysis using RegRNA 2.0
and mfold web server [35,36]. According to the analysis
of the PLK1 mRNA sequence [NCBI: NM005030] with
and without the A to G substitution, the polymorphism
is neither located within a microRNA binding site nor
hampers or generates putative regulatory RNA elements
like AU-rich motifs (data not shown). Mfold results
strongly suggest that rs27770 in the 3′UTR has a marked
effect on PLK1 mRNA structure (Figure 3A). The A and
G alleles differ considerably in their predicted most favor-
able secondary mRNA structure. Under the assumption
of a 5% suboptimality with regard to the minimum
free energy, all additionally received secondary structures
(A allele n = 30; G allele n = 39) were different between al-
leles. To study the functional impact of rs27770 alleles on
PLK1 mRNA expression, 350 bp of the 3′UTR, containing
either of the two alleles, were cloned into the pMIR-
REPORT vector downstream of the Firefly luciferase cod-
ing region and co-transfected with the Renilla luciferase
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Figure 2 In silico transcription factor binding sites and electrophoretic mobility shift assay. Schematic representation of the PLK1
silencer and core promoter regions (panel A). Alleles and the surrounding sequence of the silencer SNP rs57973275 (c.-1706G > A) and
the core promoter SNP rs16972787 (c.-233G > A) are shown. Transcription factors and their putative binding sites are shown above and
below the corresponding PLK1 alleles, respectively. Representative electrophoretic mobility shift assays for both SNPs that failed to show
genotype-dependent binding of nuclear extracts of different cell lines (panel B).
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350 bp insert is functionally relevant and improves mRNA
stability significantly in comparison with the empty vector.
Furthermore, rs27770 alleles lead to significantly altered
mRNA stability. In HEK293 cells, reporter activity of the
A allele is about 25% higher compared with the G allele.
Discussion
According to our database review and sequencing results
the coding region of PLK1 is conserved and polymor-
phisms are located in intronic and regulatory regions.
This is in line with general findings with regard to the
occurrence rate of genetic variations and especially of
SNPs in different gene regions [22]. We considered
database-derived polymorphisms with a MAF of at least
1% in Caucasians. Nevertheless, the analyzed databases
comprise a relevant number of rare variants of the cod-
ing region with MAFs of less than 1% in Caucasian that
could have a functional impact on PLK1. Some of these
variants reach a MAF of more than 1% in other ethnici-
ties (e.g. rs2230914). Due to the number of chromo-
somes investigated by sequencing, the probability to
detect new, undescribed polymorphisms with a MAF of
1% was 33% only. An adequate probability of at least
90% for detecting new polymorphisms was only reached
for polymorphisms with a MAF of more than 5%. There-
fore, it is possible that the PLK1 gene still harbors un-
detected rare variants (most likely non-SNP variations).
Furthermore, other databases that were not systematic-
ally analyzed for this study might contain additional vari-
ations with MAFs above 1% in Caucasians. For example,after completion of our experiments we became aware
of a missense variant (rs45569335) with an overall MAF
of 0.7%, but with a MAF of 1.2% within the Caucasian
subset of the 1000 genome browser [37].
We selected four candidate SNPs for further investiga-
tion, which were either located within the regulatory re-
gions of PLK1 (rs57973275, rs16972787 and rs27770) or
showed an association with bladder cancer outcome in a
previous study (rs40076). The results of the haplotype
analysis implied that it is not necessary to genotype all 4
polymorphisms in future association studies [38] and
that two tagging SNPs, either rs57973275 or rs16972787
in combination with rs27770 would be sufficient to rep-
resent the haplo- and diplotype structure of these PLK1
SNPs. Furthermore, the strong linkage disequilibrium sug-
gests rs27770 as the underlying functional SNP in the de-
tected association of the PLK1 intron 3 SNP rs40076 with
bladder cancer outcome [39].
Since the two SNPs 5′ of the coding region are located
within previously identified important regulatory regions
of PLK1 [21] they were considered eligible candidates
for bioinformatic and experimental assessment [40], and
because different software applications access different
databases, we used three in silico tools to predict putative
TF binding sites. Analysis revealed different allele-specific
candidates for both SNPs. Computational approaches for
identifying binding sites suffer from high error rates be-
cause binding motifs of TFs are typically short and degen-
erated [41], therefore, we performed EMSA experiments
using three different cell lines to validate the in silico re-
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Figure 3 Secondary PLK1 mRNA structure and reporter assays for allele-dependent mRNA stability. Mfold-predicted most favorable
secondary PLK1 mRNA structure dependent on rs27770 (c.*154A > G) alleles (panel A). Prediction is based on PLK1 mRNA sequence according to
NCBI accession number NM005030. Arrows indicate position of the polymorphism within the secondary structures. Allele-dependent activity of
PLK1 3′UTR reporter constructs expressed in HEK293 cells (panel B). Structures of the constructs used for the reporter assay are depicted on the
left side. Reporter activity was quantified by measuring Firefly luciferase activity normalized to Renilla luciferase activity. Data are mean ± SE of five
independent experiments, ***P < 0.001, **P < 0.01, one-way ANOVA and Holm-Sidak’s post-hoc multiple comparisons test.
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ing, negating any further evaluation of the SNPs with re-
gard to TF binding activity. Some authors reported that
only 33% of all functional promoter variants were found
in known consensus sequences or motifs [42], therefore,
we cannot rule out an impact of the two SNPs on binding
of other TFs which are not expressed by the selected cell
lines. Another mechanism to regulate expression is
methylation of CpG islands. Theoretically, the G allele of
the promoter polymorphism rs16972787 could be a candi-
date for allele-specific methylation, however, changes of
the methylation status in human malignant cells and tis-
sues have been reported for PLK2 and PLK3 but not for
PLK1 [12,43,44]. A further study suggested that the PLK1
promoter is unmethylated in G0/G1 (PLK1 not expressed)
as well as M phase (PLK1 expressed) and regulated during
the cell cycle by transcription factors [45].
Alleles of the 3′UTR polymorphism rs27770 were ana-
lyzed with regard to different functional RNA motifs and
microRNA binding sites. The analysis revealed neithermotif nor target site differences. Until now at least six
PLK1 mRNA-targeting microRNAs have been experi-
mentally validated [46-51]. In line with our analysis, the
predicted corresponding binding sites do not include the
polymorphism. In consideration of the secondary mRNA
structure, another key factor for microRNA target recog-
nition is the accessibility of the binding site [52]. Differ-
ent reports proposed altered microRNA binding because
of allele-dependent changes of the secondary mRNA
structure due to SNPs outside of the microRNA binding
site [53,54]. Furthermore, alterations of the secondary
structure itself can interfere with RNA-binding pro-
teins, which can lead to altered mRNA stability [55]. We
therefore investigated the secondary structure of the PLK1
mRNA dependence on rs27770 alleles. Although only one
nucleotide was substituted, major changes of the second-
ary structure were predicted. Reporter assays of the 3′
UTR of PLK1 consistently showed statistically significant
allele-dependent differences in mRNA stability. In com-
parison to the G allele, the A allele showed 25% more
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[56]. Our results, as well as a previous bioinformatic com-
parison of HapMap and dbEST data, support a functional
impact of rs27770. However, the results themselves are
contradictory, because the previous report predicted an
increased expression of the G allele [24]. This could have
several reasons. First, an experimental validation of a sub-
set of the predicted candidate SNPs confirmed only 36%
of the results and rs27770 was not part of the validation
subset. Most of the SNPs (59%) showed no differential al-
lelic expression, but alleles corresponding to 5% of the
SNPs were significantly associated with gene expression
in the opposite direction. Second, according to the usual
practice, we investigated mRNA stability of the 3′UTR by
reporter assay, however the complete PLK1 mRNA con-
tributes to the secondary structure. It is therefore possible
that the hybrid mRNA of the Firefly luciferase coding re-
gion and the PLK1 3′UTR could lead to biased re-
sults because of other secondary structures. Third, both
results could be genuine, if the effect of the SNP is
context-dependent and tissue-related. This is a well-
known phenomenon and occurs often in connection with
regulatory SNPs, especially if the SNP effect depends on
differentially expressed transcription factors and micro-
RNAs respectively [57].
Finally, genetic variability of the PLK1 gene and rs27770
in particular are interesting candidates for additional stud-
ies. Because PLK1 plays an important role in the cell cycle
and inhibits apoptosis, it should be investigated whether
PLK1 polymorphisms have an impact on proliferation of
malignant and non-malignant cells [3,5]. This would lead
to altered expression profiles in cancer tissues and might
partly explain the detected variability of PLK1 expression
in different cancer entities [8]. In some malignancies like
acute lymphoblastic leukemia (ALL) PLK1 expression is
highly variable, but expression is not associated with any
clinical or biological feature while ALL cell lines respond
very well to PLK1 inhibitor treatment [58]. For these
malignancies analysis of PLK1 polymorphisms would be
an interesting approach to reanalyze genotype-dependent
subsets with regards to expression patterns and clinical as
well as biological features. PLK1 polymorphisms could be
useful with regard to risk as well as outcome studies in
Caucasian cancer patients but also in other ethnicities be-
cause, according to dbSNP data, rs27770 occurs in other
ethnicities as well. Furthermore, functional SNPs in drug
target genes may have an impact on targeted therapy. It
would therefore be of interest to evaluate PLK1 inhibitor
studies with regard to PLK1 polymorphisms, and, because
of the predicted impact of the SNP on the secondary
mRNA structure of PLK1 and the effects shown on
mRNA stability, RNAi based PLK1 inhibitors would be of
special interest in this case. It is also well-known that the
target secondary structure has a major impact on siRNAand RNAi efficiency [59,60]. We have no evidence for an
interaction of PLK1 polymorphisms with currently clinic-
ally evaluated RNAi-based PLK1 inhibitors [61], but it
would be reasonable to analyze the respective binding
sites with regard to allele-dependent target accessibility.
Conclusions
Altogether, our results contribute to reveal the func-
tional impact of genetic variants on PLK1 function.
Based on such results, we can speculate about a putative
clinical impact: I. these variants may play a role in car-
cinogenesis and modulate the risk for cancer; II. variants
may contribute to altered tumor growth which could lead
to different disease courses; and III. PLK1 inhibitor re-
sponse might be genotype dependent. Although our ana-
lyses were not exhaustive, data presented here strongly
indicate that a relevant amount of the detectable inter-
individual variability of the PLK1 expression with con-




We have retrieved and analyzed data of genetic varia-
tions of the PLK1 gene region from NCBI dbSNP [62]
and the HapMap database [63]. To further analyze Hap-
Map data we used Haploview 4.2 [64] but none of the
currently accessible HapMap versions contained data of
all of the four polymorphisms of this study. Therefore,
Haploview was used to analyze and visualize our own data
only. Analysis of putative allele-dependent binding sites of
transcription factors due to SNPs within regulatory re-
gions of the PLK1 gene was performed with MatInspector
[29], Consite [30] and Alibaba2.1 [31] using default set-
tings. To study whether microRNA binding or regulatory
RNA motifs could be altered by SNPs, we performed ana-
lysis of the 3′UTR using RegRNA 2.0 [36]. The mRNA
sequences harboring the different rs27770 alleles were
subjected to the web-tool mfold to predict secondary
structures [35]. The full mRNA sequence of PLK1, [NCBI
RefSeq NM005030], was used for analysis. Sequences were
folded with mfold in a locally automated manner. The
structures predicted to have the lowest energy were used
to identify the folding state. For computing suboptimal
foldings the percent suboptimality value that controls the
free energy increment was set to 5%.
Sequencing of the PLK1 gene
DNA for sequencing (n = 20) and for genotyping (n = 100)
were extracted from whole blood of healthy unrelated
Caucasian blood donors, recruited at the local Depart-
ment for Transfusion Medicine, University Hospital
Essen, Germany, using the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany). This study was strictly
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was approved by the local ethics committee of the Univer-
sity Hospital Essen (073454). Informed consent was ob-
tained from all study participants. Primers listed in Table 2
were used for PCR and subsequent sequencing. Primers
for 5′UTR, coding regions and 3′UTR were designed to
investigate the exons and the corresponding exon-intron
boundaries. Relative positions of the enhancer, silencer and
core promoter region of PLK1 have been adopted from
Bräuninger et al. [21]. We used this information to design
appropriate primers that generate overlapping PCR prod-
ucts (Figure 1A).
Genotyping of PLK1 polymorphisms
The polymorphisms rs57973275, rs40076 and rs27770 were
genotyped by restriction fragment length polymorphism
analyses. For all polymerase chain reactions (PCR) the Taq
DNA Polymerase Master Mix RED (Ampliqon, Herlev,
Denmark) was used. The PCR for rs57973275 was per-
formed with following primers: 5′-TCCCTGGACTTTG
TCCATG-3′ and 5′-ACCACCTCCTAGTCTGATG-3′
resulting in a PCR product of 138 bp. Amplified frag-
ments were digested with restriction enzyme DdeI (New
England Biolabs, Beverly, MA, USA) by incubating for
4 hours at 37°C. DdeI specifically cuts PCR products that
carry the G allele (98 + 40 bp). For rs40076 an 110 bp frag-
ment was amplified from genomic DNA with the follow-
ing primers: 5′-TGTGGTCCATTGGGTGTATC-3′ and
5′-AAGGTCCACAGAAAAGGTC-3′. The variant G al-
lele generates a PsyI (Fisher Scientific, Schwerte, Germany)
restriction site that leads to two bands (50 + 60 bp). Geno-
types of rs27770 were determined using the primers 5′-
CTCCCGCGGTGCCATGTCT-3′ and 5′-CCGAACATG
TACAAAAATAACGTA-3′ and the restriction enzyme
RsaI (New England Biolabs, Ipswich, MA, USA) whichTable 2 Primers for PCR and sequencing of PLK1












Exon8 + 9 CTGGGCTCAAACAATCCTCCTCCCTCA
Exon10 TCTTCCCTCTACTCCCTAACAcuts the G allele (87 + 13 bp). For rs16972787 no appro-
priate allele-specific restriction enzyme was available and
it was therefore genotyped by Pyrosequencing. PCR was
performed using forward primer 5′-GGTCTCCGCATC
CACGCCGG-3′ and biotinylated reverse primer 5′-TC
CAAACC-CGCCCGCCGCGC-3′ resulting in a 150 bp
fragment. The DNA amplification was carried out using
Taq PCR Mastermix (Eppendorf, Hamburg, Germany).
The biotinylated strand was captured on streptavidin
coated beads, annealed with sequencing primer 5′-CC
AGGCTATCCCACGTGTT-3′ and sequenced with a
PyroMark Q96 MD (Qiagen, Hilden, Germany). Results
were analyzed using the PSQ96 SNP software (Qiagen,
Hilden, Germany). Adequate negative and positive con-
trols were used for genotyping of all SNPs. Accuracy of
genotyping was additionally validated by direct sequencing
of 10% randomly selected samples and of the samples har-
boring rare haplotypes with a frequency under 1%. This
revealed complete concordance with previous results.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from HEK293, HeLa and HepG2 cells
were prepared using the NuCLEAR™ extraction kit (Sigma,
Deisenhofen, Germany) and stored at −80°C until use.
EMSAs were done with the DIG Gel Shift kit (Roche
Applied Science, Mannheim, Germany) using digo-
xigenin (DIG)-labeled double-stranded oligonucleotides.
The double-stranded oligonucleotides were made of syn-





rs16972787 G allele 5′-CCACGTGTTCGGGCGTCCGT
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TGTCAAT-3′ and 5′-ATTGACACGGACGCCTGAACA
CGTGG-3′. Single-stranded oligonucleotides (200 pmol)
were mixed in TEN buffer (10 mM Tris, 1 mM EDTA,
0.1 M NaCl, pH 8.0), incubated at 95°C for 10 min and
chilled on ice to let oligonucleotides anneal. Double-
stranded oligonucleotides (3.85 pmol) were DIG labeled
and equal labelling efficiency was verified by dot blot ana-
lysis. Probes were incubated with 10 μg nuclear ex-
tracts for 20 min at room temperature followed by
non-denaturating 6% polyacrylamide gel electrophor-
esis with 0.5-fold TBE running buffer (45 mM Tris,
45 mM boric acid, 1 mM EDTA, pH 8.0). Controls
contained labeled probe alone and competition exper-
iments were performed with an additional 250-fold molar
excess of unlabeled probe. EMSAs were performed in
triplicate for every cell line and both polymorphisms.
DNA-protein complexes were electroblotted to posi-
tively charged nylon membranes (Roche, Mannheim,
Germany) and the band shifts were visualized accord-
ing to the user’s manual for the DIG Gel Shift kit.
Transient transfection of HEK293 cells and luciferase
reporter assay
The 3′UTR of PLK1 was PCR-amplified from genomic
DNA and cloned in the pGEM-T Easy Vector (Promega,
Madison, WI, USA). The amplified 3′UTR was restricted
from the pGEM-T Vector and cloned downstream of
the Firefly luciferase coding region into the pMIR-
REPORT™ vector (Applied Biosystems, Foster City, CA).
HEK293 cells were plated into 96-well plates at a density
of 1,5 × 104 cells/well in 100 μl of DMEM medium with
10% FBS. After 24 h co-transfections were carried out in
50 μl of DMEM medium without serum using 150 ng of
the respective pMIR reporter construct and 50 ng of
Renilla luciferase control vector (pGL4.74, Promega,
Madison, WI, USA) containing 0.5 μl of Lipofectamine
2000 (Invitrogen, Karlsruhe, Germany) per transfection
according to the manufacturer’s instructions. After 6 h,
the transfection mix was removed, and cells were incu-
bated with new DMEM medium. 24 hours after treat-
ment, cells were harvested and assayed for Firefly and
Renilla luciferase activities using the Dual-Glo Luciferase
Assay System (Promega, Madison, WI, USA) on a Lumat
LB 9501 Luminometer (Berthold, Bad Wildbad, Germany).
To correct for variable transfection efficiency Firefly lucif-
erase activity was normalized to Renilla luciferase activity.
Statistical analysis
Control for deviation from the Hardy–Weinberg equilib-
rium was conducted with a web-tool by Rodriguez et al.
[65]. Linkage disequilibrium and haplotypes were assessed
using Haploview [64]. One-way ANOVA was used to
analyze the overall difference of reporter activities. Tocorrect for multiple comparisons Holm-Sidak’s post-hoc
multiple comparisons test was used for pairwise compari-
sons of reporter activities. All statistical analyses were per-
formed using GraphPad Prism 6.0 (GraphPad Software,
San Diego, CA, USA). Differences were regarded as sig-
nificant at p < 0.05.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors read and approved the final manuscript. KR, JW, WS and HSB
contributed to conception and design of the study. NA, KR, JW, JH and HSB
performed in silico analyses and functional assays. NA, WS and HSB
contributed to data analysis and interpretation. NA, JH, WS and HSB drafted
and revised the manuscript.
Author details
1Institute of Pharmacogenetics, University Hospital Essen, Hufelandstr. 55,
45147 Essen, Germany. 2Department of Urology, University Hospital Essen,
Hufelandstr. 55, 45147 Essen, Germany.
Received: 11 September 2013 Accepted: 15 April 2014
Published: 26 April 2014
References
1. Strebhardt K, Ullrich A: Targeting polo-like kinase 1 for cancer therapy.
Nat Rev Cancer 2006, 6:321–330.
2. Wang Y, Ji P, Liu J, Broaddus RR, Xue F, Zhang W: Centrosome-associated
regulators of the G(2)/M checkpoint as targets for cancer therapy.
Mol Cancer 2009, 8:8.
3. Zhang L, Shao H, Huang Y, Yan F, Chu Y, Hou H, Zhu M, Fu C, Aikhionbare F,
Fang G, Ding X, Yao X: PLK1 phosphorylates mitotic centromere-associated
kinesin and promotes its depolymerase activity. J Biol Chem 2011,
286:3033–3046.
4. Goto H, Kiyono T, Tomono Y, Kawajiri A, Urano T, Furukawa K, Nigg EA,
Inagaki M: Complex formation of Plk1 and INCENP required for
metaphase-anaphase transition. Nat Cell Biol 2006, 8:180–187.
5. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M,
Nakagawara A: Polo-like kinase 1 (Plk1) inhibits p53 function by physical
interaction and phosphorylation. J Biol Chem 2004, 279:25549–25561.
6. Saxena M, Singh S, Negi MP, Srivastava AK, Trivedi R, Singh U, Pant MC,
Bhatt ML: Expression profiling of G2/M phase regulatory proteins in
normal, premalignant and malignant uterine cervix and their correlation
with survival of patients. J Cancer Res Ther 2010, 6:167–171.
7. Winkles JA, Alberts GF: Differential regulation of polo-like kinase 1, 2, 3,
and 4 gene expression in mammalian cells and tissues. Oncogene 2005,
24:260–266.
8. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H,
Strebhardt K: Induction and down-regulation of PLK, a human serine/
threonine kinase expressed in proliferating cells and tumors. Proc Natl
Acad Sci U S A 1994, 91:1736–1740.
9. He ZL, Zheng H, Lin H, Miao XY, Zhong DW: Overexpression of polo-like
kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.
World J Gastroenterol 2009, 15:4177–4182.
10. Bieche I, Vacher S, Lallemand F, Tozlu-Kara S, Bennani H, Beuzelin M, Driouch
K, Rouleau E, Lerebours F, Ripoche H, Cizeron-Clairac G, Spyratos F, Lidereau
R: Expression analysis of mitotic spindle checkpoint genes in breast
carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a
two-gene signature for aneuploidy. Mol Cancer 2011, 10:23.
11. Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C,
Sakano S, Furuya T, Oga A, Naito K, Sasaki K: Overexpression of polo-like
kinase 1 (PLK1) and chromosomal instability in bladder cancer.
Oncology 2006, 70:231–237.
12. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, Dombrowski F,
Schirmacher P, Longerich T: Oncogenic and tumor suppressive roles of
polo-like kinases in human hepatocellular carcinoma. Hepatology 2010,
51:857–868.
13. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, Muller
BM, Niesporek S, Dietel M, Denkert C: Polo-like kinase isoforms in breast
Akdeli et al. Molecular Cancer 2014, 13:87 Page 9 of 10
http://www.molecular-cancer.com/content/13/1/87cancer: expression patterns and prognostic implications. Virchows Arch
2005, 446:442–450.
14. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, Ozaki M, Ito H,
Ikeguchi M: Expression of polo-like kinase 1 (PLK1) protein predicts the
survival of patients with gastric carcinoma. Oncology 2006, 70:126–133.
15. Wang R, Song Y, Xu X, Wu Q, Liu C: The expression of Nek7, FoxM1, and
Plk1 in gallbladder cancer and their relationships to clinicopathologic
features and survival. Clin Transl Oncol 2013, 15:626–632.
16. Garuti L, Roberti M, Bottegoni G: Polo-like kinases inhibitors. Curr Med
Chem 2012, 19:3937–3948.
17. Korzeniewski N, Hohenfellner M, Duensing S: The centrosome as potential
target for cancer therapy and prevention. Expert Opin Ther Targets 2013,
17:43–52.
18. Burnett JC, Rossi JJ: RNA-based therapeutics: current progress and future
prospects. Chem Biol 2012, 19:60–71.
19. Clay FJ, McEwen SJ, Bertoncello I, Wilks AF, Dunn AR: Identification and
cloning of a protein kinase-encoding mouse gene, Plk, related to the
polo gene of Drosophila. Proc Natl Acad Sci U S A 1993, 90:4882–4886.
20. Hamanaka R, Maloid S, Smith MR, O’Connell CD, Longo DL, Ferris DK:
Cloning and characterization of human and murine homologues
of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994,
5:249–257.
21. Brauninger A, Strebhardt K, Rubsamen-Waigmann H: Identification and
functional characterization of the human and murine polo-like kinase
(Plk) promoter. Oncogene 1995, 11:1793–1800.
22. Tabor HK, Risch NJ, Myers RM: Candidate-gene approaches for studying
complex genetic traits: practical considerations. Nat Rev Genet 2002,
3:391–397.
23. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM: Silent polymor-
phisms speak: how they affect pharmacogenomics and the treatment of
cancer. Cancer Res 2007, 67:9609–9612.
24. Ge B, Gurd S, Gaudin T, Dore C, Lepage P, Harmsen E, Hudson TJ, Pastinen
T: Survey of allelic expression using EST mining. Genome Res 2005,
15:1584–1591.
25. Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey
KT, Marsit CJ, Moore JH, Karagas MR: Bladder cancer SNP panel predicts
susceptibility and survival. Hum Genet 2009, 125:527–539.
26. den Dunnen JT, Antonarakis SE: Nomenclature for the description of
human sequence variations. Hum Genet 2001, 109:121–124.
27. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ: Cancer
pharmacogenomics: strategies and challenges. Nat Rev Genet 2013,
14:23–34.
28. Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, Grimstein
C, Pacanowski M, Ehmann F, Dossena S, Paulmichl M: Pharmacogenetics in
the evaluation of new drugs: a multiregional regulatory perspective.
Nat Rev Drug Discov 2013, 12:103–115.
29. Quandt K, Frech K, Karas H, Wingender E, Werner T: MatInd and
MatInspector: new fast and versatile tools for detection of consensus
matches in nucleotide sequence data. Nucleic Acids Res 1995,
23:4878–4884.
30. Sandelin A, Wasserman WW, Lenhard B: ConSite: web-based prediction of
regulatory elements using cross-species comparison. Nucleic Acids Res
2004, 32:W249–W252.
31. Grabe N: AliBaba2: context specific identification of transcription factor
binding sites. In Silico Biol 2002, 2:S1–15.
32. Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang
Z, Lu F, Zhang H: Dissecting the phenotypes of Plk1 inhibition in cancer
cells using novel kinase inhibitory chemical CBB2001. Lab Invest 2012,
92:1503–1514.
33. Vitour D, Dabo S, Ahmadi PM, Vilasco M, Vidalain PO, Jacob Y, Mezel-
Lemoine M, Paz S, Arguello M, Lin R, Yang J, Chen L, Zhao X, Wei Y: Polo-
like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. J Biol
Chem 2009, 284:21797–21809.
34. Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J,
Yang J, Chen L, Zhao X, Wei Y: Intravenous liposomal delivery of the short
hairpin RNAs against Plk1 controls the growth of established human
hepatocellular carcinoma. Cancer Biol Ther 2011, 11:401–409.
35. Zuker M: Mfold web server for nucleic acid folding and hybridization
prediction. Nucleic Acids Res 2003, 31:3406–3415.
36. Chang TH, Huang HY, Hsu JB, Weng SL, Horng JT, Huang HD: An enhanced
computational platform for investigating the roles of regulatory RNAand for identifying functional RNA motifs. BMC Bioinformatics 2013,
14(Suppl 2):S4.
37. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles
ME, McVean GA: A map of human genome variation from population-
scale sequencing. Nature 2010, 467:1061–1073.
38. Stram DO: Tag SNP selection for association studies. Genet Epidemiol 2004,
27:365–374.
39. Garner C, Slatkin M: On selecting markers for association studies:
patterns of linkage disequilibrium between two and three diallelic
loci. Genet Epidemiol 2003, 24:57–67.
40. Chorley BN, Wang X, Campbell MR, Pittman GS, Noureddine MA, Bell DA:
Discovery and verification of functional single nucleotide
polymorphisms in regulatory genomic regions: current and developing
technologies. Mutat Res 2008, 659:147–157.
41. Hannenhalli S: Eukaryotic transcription factor binding sites–modeling and
integrative search methods. Bioinformatics 2008, 24:1325–1331.
42. Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O’Donovan
MC: Strong bias in the location of functional promoter polymorphisms.
Hum Mutat 2005, 26:214–223.
43. Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G,
Bourantas KL, Crook T: Polo-like kinase 2 (SNK/PLK2) is a novel
epigenetically regulated gene in acute myeloid leukemia and
myelodysplastic syndromes: genetic and epigenetic interactions.
Ann Hematol 2011, 90:1037–1045.
44. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I,
Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T: Polo-like kinase
Plk2 is an epigenetic determinant of chemosensitivity and clinical
outcomes in ovarian cancer. Cancer Res 2011, 71:3317–3327.
45. Kelly TK, Miranda TB, Liang G, Berman BP, Lin JC, Tanay A, Jones PA: H2A.Z
maintenance during mitosis reveals nucleosome shifting on mitotically
silenced genes. Mol Cell 2010, 39:901–911.
46. Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, Sun G, Tong T, He J, Shi Y, Zhang
X, Lu N, He Y, Zhang H, Ma K, Luo X, Lv L, Deng H, Cheng J, Zhu J, Wang L,
Zhan Q: DNA methylation-mediated repression of miR-886-3p predicts
poor outcome of human small cell lung cancer. Cancer Res 2013,
73:3326–3335.
47. He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB, Zhang Y: MiR-210
disturbs mitotic progression through regulating a group of mitosis-
related genes. Nucleic Acids Res 2013, 41:498–508.
48. Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX: MicroRNA-100 is a potential
molecular marker of non-small cell lung cancer and functions as a tumor
suppressor by targeting polo-like kinase 1. BMC Cancer 2012, 12:519.
49. Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B,
Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R,
Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G:
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in hu-
man breast tumours. EMBO Mol Med 2012, 4:1214–1229.
50. Ito T, Sato F, Kan T, Cheng Y, David S, Agarwal R, Paun BC, Jin Z, Olaru AV,
Hamilton JP, Selaru FM, Yang J, Matsumura N, Shimizu K, Abraham JM,
Shimada Y, Mori Y, Meltzer SJ: Polo-like kinase 1 regulates cell
proliferation and is targeted by miR-593* in esophageal cancer. Int J
Cancer 2011, 129:2134–2146.
51. Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, Busson P, Lo KW,
Ng R, Waldron J, O’Sullivan B, Liu FF: Significance of Plk1 regulation
by miR-100 in human nasopharyngeal cancer. Int J Cancer 2010,
126:2036–2048.
52. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E: The role of site
accessibility in microRNA target recognition. Nat Genet 2007, 39:1278–1284.
53. Abrahams Y, Laguette MJ, Prince S, Collins M: Polymorphisms within the
COL5A1 3′-UTR that alters mRNA structure and the MIR608 gene are
associated with Achilles tendinopathy. Ann Hum Genet 2013, 77:204–214.
54. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino
JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate
reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A
2007, 104:13513–13518.
55. Li X, Quon G, Lipshitz HD, Morris Q: Predicting in vivo binding sites of
RNA-binding proteins using mRNA secondary structure. RNA 2010,
16:1096–1107.
56. Cheneval D, Kastelic T, Fuerst P, Parker CN: A review of methods to
monitor the modulation of mRNA stability: a novel approach to drug
discovery and therapeutic intervention. J Biomol Screen 2010, 15:609–622.
Akdeli et al. Molecular Cancer 2014, 13:87 Page 10 of 10
http://www.molecular-cancer.com/content/13/1/8757. Fu J, Wolfs MG, Deelen P, Westra HJ, Fehrmann RS, Te Meerman GJ,
Buurman WA, Rensen SS, Groen HJ, Weersma RK, van den Berg LH, Veldink
J, Ophoff RA, Snieder H, van Heel D, Jansen RC, Hofker MH, Wijmenga C,
Franke L: Unraveling the regulatory mechanisms underlying tissue-
dependent genetic variation of gene expression. PLoS Genet 2012,
8:e1002431.
58. Oliveira JC, Pezuk JA, Brassesco MS, Morales AG, Queiroz RG, Scrideli CA,
Tone LG: PLK1 expression and BI 2536 effects in childhood acute
lymphoblastic leukemia. Pediatr Blood Cancer. In press.
59. Chen J, Zhang W: Kinetic analysis of the effects of target structure on
siRNA efficiency. J Chem Phys 2012, 137:225102.
60. Shao Y, Chan CY, Maliyekkel A, Lawrence CE, Roninson IB, Ding Y: Effect of
target secondary structure on RNAi efficiency. RNA 2007, 13:1631–1640.
61. Ramanathan RK, Hamburg SI, Borad MJ, Seetharam M, Kundranda MN,
Lee P, Fredlund P, Gilbert M, Mast C, Semple SC, Judge AD, Crowell B,
Vocila L, MacLachlan I, Northfelt DW: A phase I dose escalation study of
TKM-080301, aRNAi therapeutic directed against PLK1, in patients with
advanced solid tumors. Proc 104th Annu Meet AACR 2013, 2013:LB-289.
62. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K:
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001,
29:308–311.
63. International HapMap Consortium: The International HapMap Project.
Nature 2003, 426:789–796.
64. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263–265.
65. Rodriguez S, Gaunt TR, Day IN: Hardy-Weinberg equilibrium testing of
biological ascertainment for Mendelian randomization studies. Am J
Epidemiol 2009, 169:505–514.
doi:10.1186/1476-4598-13-87
Cite this article as: Akdeli et al.: A 3′UTR polymorphism modulates
mRNA stability of the oncogene and drug target Polo-like Kinase 1.
Molecular Cancer 2014 13:87.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
